CommercialCoverageMedium impact
06.02.53, Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Independence Blue Cross·Urology, Oncology·Medical Policy
Effective date
Jan 27, 2025
We identified it
Jun 19, 2026
Summary
This is a NEW policy (effective 01/27/2025) establishing coverage criteria and clinical guidelines for protein biomarkers in prostate cancer diagnosis and cancer risk assessment. The billing team must obtain the full policy details to identify specific CPT/HCPCS codes, prior authorization requirements, and documentation standards before processing claims for these services.
Action Required
By 02/15/2025: Billing team must obtain and review the complete policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=01&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-06-02-53. Extract specific CPT/HCPCS codes for protein biomarker testing (e.g., PSA, 4Kscore, PHI, etc.). Determine if prior authorization is required and update billing system rules accordingly. Brief providers and front desk staff on any new documentation requirements. Update encounter forms and superbills to reflect covered biomarkers and any medical necessity criteria. Test billing workflows to ensure compliance before processing claims.